Reports Q1 revenue $969,000, consensus $1.1M. Over 1,200 KidneyIntelX tests performed in the first quarter of fiscal 2023, a record, of which over 80% were billable, yielding approximately $1.0 million revenue.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RNLX:
- Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
- Renalytix announces publication highlighting KidneyIntelX test
- Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
- Renalytix to Present at Stifel Healthcare Conference
- Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31